WascoMJ, DaignaultS, ZhangY et al.. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology2007;70:69–74.
WascoMJDaignaultSZhangY. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007;70:69–74.
)| false
HerrHW, ShipleyWU, BajorinDF. Cancer of the bladder. In: DeVitaVT, HellmanS, RosenbergSA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
HerrHWShipleyWUBajorinDF. Cancer of the bladder. In: DeVitaVTHellmanSRosenbergSA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001.
)| false
HallRR, ParmarMK, RichardsAB, SmithPH. Changes in cystoscopic follow up in patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ1994;308:257–260.
HallRRParmarMKRichardsABSmithPH. Changes in cystoscopic follow up in patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994;308:257–260.
)| false
SmithJAJr, LabaskyRF, CockettAT et al.. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). J Urol1999;162:1697–1701.
SmithJAJrLabaskyRFCockettAT. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS). J Urol 1999;162:1697–1701.
)| false
DuttaSC, SmithJAJr, ShappellSB et al.. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol2001;166:490–493.
DuttaSCSmithJAJrShappellSB. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001;166:490–493.
)| false
ShelleyMD, KynastonH, CourtJ et al.. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection versus transurethral resection alone in Ta and T1 bladder cancer. BJU Int2001;88:209–216.
ShelleyMDKynastonHCourtJ. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection versus transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209–216.
)| false
HanRF, PanJG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology2006;67:1216–1223.
HanRFPanJG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216–1223.
)| false
ShelleyMD, WiltTJ, CourtJ et al.. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int2004;93:485–490.
ShelleyMDWiltTJCourtJ. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485–490.
)| false
BohleA, JochamD, BockPR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol2003;169:90–95.
BohleAJochamDBockPR. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90–95.
)| false
JoudiFN, SmithBJ, O’DonnellMA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol2006;24:344–348.
JoudiFNSmithBJO’DonnellMA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006;24:344–348.
)| false
BohleA, BockPR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology2004;63:682–686; discussion 686–687.
BohleABockPR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682–686; discussion 686–687.
)| false
ShelleyMD, WiltTJ, CourtJ et al.. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int2004;93:485–490.
ShelleyMDWiltTJCourtJ. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485–490.
)| false
SylvesterRJ, van der MeijdenAP, LammDL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta analysis of the published results of randomized clinical trials. J Urol2002;168:1964–1970.
SylvesterRJvan der MeijdenAPLammDL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta analysis of the published results of randomized clinical trials. J Urol 2002;168:1964–1970.
)| false
SylvesterRJ, van der MeijdenAP, WitjesJA, KurthK. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol2005;174:86–91; discussion 91–82.
SylvesterRJvan der MeijdenAPWitjesJAKurthK. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86–91; discussion 91–82.
)| false
HanRF, PanJG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology2006;67:1216–1223.
HanRFPanJG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216–1223.
)| false
KimB, SemelkaRC, AscherSM et al.. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enchanced imaging, and late gadolinium-enhancing imaging. Radiology1994;193:239–245.
KimBSemelkaRCAscherSM. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enchanced imaging, and late gadolinium-enhancing imaging. Radiology 1994;193:239–245.
)| false
GrossmanHB, NataleRB, TangenCM et al.. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med2003;349:859–866.
GrossmanHBNataleRBTangenCM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859–866.
)| false
SherifA, HolmbergL, RintalaE et al.. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol2004;45:297–303.
SherifAHolmbergLRintalaE. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004;45:297–303.
)| false
WinquistE, KirchnerTS, SegalR et al.. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol2004;171:561–569.
WinquistEKirchnerTSSegalR. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004;171:561–569.
)| false
LehmannJ, RetzM, WiemersC et al.. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol2005;23:4963–4974.
LehmannJRetzMWiemersC. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 2005;23:4963–4974.
)| false
StöckleM, MeyenburgW, WellekS et al.. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol1992;148:302–307.
StöckleMMeyenburgWWellekS. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992;148:302–307.
)| false
LehmannJ, FranzaringL, ThüroffJ et al.. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int2006;97:42–47.
LehmannJFranzaringLThüroffJ. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int 2006;97:42–47.
)| false
LoehrerPJSr, EinhornLH, ElsonPJ et al.. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol1992;10:1066–1073.
LoehrerPJSrEinhornLHElsonPJ. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066–1073.
)| false
LorussoV, ManzioneL, de VitaF et al.. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol2000;164:53–56.
LorussoVManzioneLde VitaF. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 2000;164:53–56.
)| false
RobertsJT, von der MaaseH, SengeløvL et al.. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol2006;17 (Suppl 5):v118–122.
RobertsJTvon der MaaseHSengeløvL. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 2006;17 (Suppl 5):v118–122.
)| false
ShipleyWU, WinterKA, KaufmanDS et al.. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of RTOG 89-03. J Clin Oncol1998;16:3576–3583.
ShipleyWUWinterKAKaufmanDS. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of RTOG 89-03. J Clin Oncol 1998;16:3576–3583.
)| false
RussellKJ, BoileauMA, HiganoC et al.. Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys1990;19:693–699.
RussellKJBoileauMAHiganoC. Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys 1990;19:693–699.
)| false
RussellKJ, BoileauMA, IretonRC et al.. Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study. Radiology1988;167:845–848.
RussellKJBoileauMAIretonRC. Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study. Radiology 1988;167:845–848.
)| false
HoussetM, MaulardC, ChretienY et al.. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol1993;11:2150–2157.
HoussetMMaulardCChretienY. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150–2157.
)| false
OrsattiM, CurottoA, CanobbioL et al.. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys1995;33:173–178.
OrsattiMCurottoACanobbioL. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 1995;33:173–178.
)| false
ZietmanAL, ShipleyWU, KaufmanDS et al.. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol1998;160:1673–1677.
ZietmanALShipleyWUKaufmanDS. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998;160:1673–1677.
)| false
KauffmanD, RaghavanD, CarducciM et al.. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol2000;18:1921–1927.
KauffmanDRaghavanDCarducciM. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;18:1921–1927.
)| false
SternbergCN, de MulderPH, SchornagelJH et al.. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol No. 30924. J Clin Oncol2001;19:2638–2646.
SternbergCNde MulderPHSchornagelJH. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol No. 30924. J Clin Oncol 2001;19:2638–2646.
)| false
Von der MaaseH, HansenSW, RobertsJT et al.. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol2000;18:3068–3077.
Von der MaaseHHansenSWRobertsJT. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068–3077.
)| false
LorussoV, ManzioneL, de VitaF et al.. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol2000;164:53–56.
LorussoVManzioneLde VitaF. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 2000;164:53–56.
)| false
MeluchAA, GrecoFA, BurrisHAIII et al.. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol2001;19:3018–3024.
MeluchAAGrecoFABurrisHAIII. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001;19:3018–3024.
)| false
DreicerR, ManolaJ, SchneiderDJ et al.. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer2003;97:2743–2747.
DreicerRManolaJSchneiderDJ. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 2003;97:2743–2747.
)| false
BellmuntJ, GuillemV, Paz-AresL et al.. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol2000;18:3247–3255.
BellmuntJGuillemVPaz-AresL. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000;18:3247–3255.
)| false
HussainM, VaishampayanU, DuW et al.. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol2001;19:2527–2533.
HussainMVaishampayanUDuW. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19:2527–2533.
)| false
SweeneyCJ, RothBJ, KabbinavarFF et al.. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol2006;24:3451–3457.
SweeneyCJRothBJKabbinavarFF. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006;24:3451–3457.
)| false
